31 "Breast" clinical trials found.
-
A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)
This is a study that is divided into two phases: Phase 1b and Phase 2. The Phase 1b part will test different combinations of drugs ...
-
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The purpose of the study is to determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the ... -
NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I HORMONE SENSITIVE HER2-NEGATIVE ONCOTYPE RECURRENCE SCORE = 18 BREAST CANCER
The purpose of the study is to determine and examine whether breast conservation surgery and endocrine therapy results in a non-inferior rate of ipsilateral-breast tumor ...
-
The Safety and Effectiveness of DuraSorb for Lower Pole Reinforcement in Patients Undergoing 2 Stage Breast Reconstruction
The purpose of this research is to test the safety and performance of DuraSorb® mesh when used to support your expander during 2-stage breast reconstruction ... -
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
This study is for patients with early-stage triple-negative breast cancer who received a treatment called pembrolizumab (a medicine used to treat melanoma). Some patients will ... -
Partial breast re-irradiation using ultra hypofractionation (PRESERVE)
This study is for patients who have had breast cancer come back in the same breast where they had surgery and radiation treatment before. This ...
-
A single arm phase II study of ADjuvant Endocrine therapy subcutaneous Pertuzumab and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive HER2-positive breast cancer (ADEPT)
You can participate in this study if you are diagnosed with stage I, hormone receptor-positive (HR+) and human epidermal growth factor receptor-2.positive (HER2+) breast ...
-
I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2
The I-SPY 2.2 study is a way to improve how we treat breast cancer. It uses a plan to test new treatments and find ...
-
A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
In stage 1 (early) HER2+ breast cancer, lesser chemotherapy is needed to achieve excellent long-term survival. The current standard therapy is TH (paclitaxel plus trastuzumab ... -
A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients with Triple Negative Breast Cancer That Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
This is a large global study for people with a type of breast cancer called triple-negative breast cancer (TNBC). It's happening in many hospitals ...